D. Manfreda

Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.

H. Samonigg, P. Sevelda, H. Hausmaninger, 1989, Onkologie.

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

R. Greil, M. Gnant, P. Dubsky, 2018 .

Steroid hormone receptors and prognosis in breast cancer

O. Dapunt, G. Kemmler, H. Hausmaninger, 1988, Breast Cancer Research and Treatment.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

M. Gnant, H. Samonigg, R. Jakesz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Comparison between the biochemical and histochemical determination of hormone receptors in breast carcinomas].

G. Daxenbichler, D. Manfreda, H. Aigner, 1985, Onkologie.

Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial

R. Greil, J. Bergh, F. Kainberger, 2016 .

Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.

H. Samonigg, P. Sevelda, H. Hausmaninger, 1995, European journal of cancer.